ERF (Gene)

Organism:

Homo sapiens

Synonyms:CHYTS, CRS4, ENTREZ:2077, ERF, ETS2 repressor factor, HGNC:3444, MIM:611888, NM_001301035, NM_001308402, NM_001312656, NM_006494, NP_001287964, NP_001295331, NP_001299585, NP_006485, PE-2, PE2, XM_017026468, XM_017026469, XP_016881957, XP_016881958

Id:ENSG00000105722

Entrez:2077

Ensembl:ENSG00000105722

Description:ETS2 repressor factor

ETS2 is a transcription factor and protooncogene involved in development, apoptosis, and the regulation of telomerase. The protein encoded by this gene binds to the ETS2 promoter and is a strong repressor of ETS2 transcription. Several transcript variants encoding two different isoforms have been found for this gene. [provided by RefSeq, Aug 2015]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View ERF's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with ERF.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using ERF.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for ERF.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with ERF.

Results found

Linked to

	Label	Description
	GSE261563 CX-5461 6 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE147662 3 V 1 NICOTINAMIDE MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE196035 GSE196037 MEN1 inhibition 5 v 11 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE158456 2 V 3 FURIN MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE213588 trametinib NF1 8 v 11 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE147876 GSE147877 enzalutamide MR42D 4 v 10 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE228263 FDX1 overexpression SU-DHL-4 Elesclomol 0 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE228263 elesclomol SU-DHL-4 0 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE133683 1 V 5 DOXORUBICIN MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE236896 GSE237665 DNMT EZH2 inhibition 1 v 5 human dn Gene Set (Entity type)	A Gene Set from LINCS

GSE261563 CX-5461 6 v 1 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE147662 3 V 1 NICOTINAMIDE MOUSE UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE196035 GSE196037 MEN1 inhibition 5 v 11 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE158456 2 V 3 FURIN MOUSE DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE213588 trametinib NF1 8 v 11 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE147876 GSE147877 enzalutamide MR42D 4 v 10 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE228263 FDX1 overexpression SU-DHL-4 Elesclomol 0 v 1 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE228263 elesclomol SU-DHL-4 0 v 1 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE133683 1 V 5 DOXORUBICIN MOUSE UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE236896 GSE237665 DNMT EZH2 inhibition 1 v 5 human dn

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.